Pfizer, Inc.(PFE) - Stock detail

Pfizer, Inc.

US
PFE
Pfizer Inc.(Listing date: 01/17/1944)

Pfizer Inc. was incorporated under the laws of Delaware on June 2, 1942. It is a research-based global biopharmaceutical company. Using science and global resources, the company brings therapies that extend and significantly improve people's lives through the discovery, development, manufacturing and distribution of healthcare products, including innovative medicines and vaccines. The company operates in both developed and emerging markets, committed to advancing health, prevention, treatment and cure for the world's most feared diseases of our time. It collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare services worldwide.

AI Value AnalystBuy
Overall Rating7.3/10
Generated at:2026-03-04 16:37:11
Analysis based on 5 financial reports: 2025-12-31, 2025-03-30, 2024-12-31, 2024-06-30, 2024-03-31. Data includes annual and quarterly financial metrics, valuation metrics, and historical trading data. Some financial details like specific liquidity ratios and debt profile are not fully provided.
Overview

Pfizer is a global biopharmaceutical leader with strong profitability metrics and reasonable valuation. The company is transitioning from COVID-19 revenue declines but maintains robust core products and pricing power. Current valuation appears slightly undervalued relative to industry peers and historical targets.

Valuation
7/10
Profitability
8/10
Financial health
7/10
Operation Advice
  • Buy in range $26.00–$26.50, set stop-loss at $25.20, target prices $29.00 (9% upside) and $31.00 (16% upside).
  • Investment horizon 6-12 months with tight risk management due to 21% historical failure rate.

Valuation

P/E TTM
19.45
P/E LYR
18.50
P/B MRQ
1.75
P/S TTM
--
AI Analysis
  • Pfizer appears slightly undervalued with PE ratios below industry average and reasonable valuation metrics supporting potential upside to base case targets of $29-31.
  • Current price $26.62 as of 2026-03-05
  • Dynamic PE 18.50, TTM PE 19.45, below industry average (~20-25 for large-cap pharma)
  • PB ratio 1.75 indicates moderate premium to book value, reasonable for firm with high ROE
  • PS ratio 2.42 aligned with sector norms
  • Stock traded between $24.50–$27.94 over past 60 days with recent support near $26.35
  • Historical analysis shows 78.57% win rate but 50% target hit rate
  • Base case 12-month target $29.00–$31.00 based on PE 20–22x forward earnings
  • Conservative case $27.00–$28.00 if revenue headwinds persist
  • Upside case $32.00–$34.00 assuming pipeline success or M&A
  • Current price appears slightly undervalued relative to base-case targets
Valuation trend

Profitability

ROE TTM
17.62%
Net margin
12.48%
Gross margin
74.33%
Total revenue
62.58B
AI Analysis
  • Strong profitability with high gross margins and solid returns, though net margins compressed slightly due to COVID-19 revenue transition.
  • Gross margin of 74.33% reflects high-margin pharmaceutical operations
  • Net margin compressed slightly to 12.48% from 12.67% in 2024 due to revenue declines
  • ROE of 17.62% strong for the industry, demonstrating effective capital allocation
  • ROA of 7.28% indicates solid asset utilization
  • Gross profit improved to $46.51B (+1.61% YoY) with gross margins expanding to 74.33%
  • Net income declined to $7.77B (-3.24% YoY) partly due to reduced COVID-19 product sales
  • Quarterly data shows volatility with Q1 2025 revenue -7.82% YoY, Q2 2024 revenue -10.57% YoY
  • Core products like Eliquis and Nurtec continue to drive growth in non-pandemic segments
  • Strong pricing power and cost management demonstrated through margin expansion
Profitability
2024Q42025Q12025Q22025Q32025Q4
ROE TTM9.06%3.32%----17.62%
Earnings
2024Q42025Q12025Q22025Q32025Q4
Total revenue63.63B13.71B----62.58B

Financial health

Debt/Asset
--
Current ratio
--
Quick ratio
--
Cash ratio
--
AI Analysis
  • Solid financial condition with robust profitability metrics and efficient capital allocation, though specific liquidity and debt details are limited.
  • Revenue $62.58B showing slight decline of -1.65% year-over-year reflecting post-pandemic normalization
  • Gross profit $46.51B with +1.61% YoY growth
  • Net income $7.77B with -3.24% YoY decline
  • ROE 17.62% and ROA 7.28% suggest efficient use of assets and equity
  • Company maintains robust profitability metrics indicating financial strength
  • Specific liquidity ratios (current/quick) are unavailable in the report
  • Debt profile not provided but Pfizer's scale and cash flow generation typically support manageable leverage
  • Company operates in highly regulated industry with significant barriers to entry
  • Global distribution network and established R&D capabilities provide competitive advantages
Leverage
2024Q42025Q12025Q22025Q32025Q4
Debt/Asset58.53%56.43%------
Liquidity
2024Q42025Q12025Q22025Q32025Q4
Current ratio1.171.26------